Chronic Infections & Hyperbaric Therapy
Mold Illness,EBV,PANDAS/PANS,Lyme Disease,etc.are all examples of chronic infections. A wide variety of infections stem from viruses, bacteria,and fungi.
Acute infections treated unsuccessfully can burrow deep into bone, organs (including the brain), or biofilm where they are able to proliferate and die without impact by the immune system and medications.
As infections continue to spread, inflammation can cause symptoms that can
include: fever, pain, brain fog,mobility dysfunction, digestive issues, and more.
When mold,viruses,and bacteria die,they release toxins into the bloodstream that can cause the symptoms to "flare" and become increasingly severe.
Hyperbaric Therapy is often used as an adjunctive modality in treating chronic infections,such as Lyme Disease,Mold Illness,Pediatric Autoimmune Neuropsychiatric Disorders (PANDAS/PANS), and Epstein Barr Virus.
Many practitioners prescribe HBOT to assist with:
·Killing anaerobic organisms and biofilm
Detoxifying endotoxins, mycotoxins,etc.
Reducing inflammation
Reducing “flare-up"symptoms
Enhancing effectiveness of other treatments
Improving immune response
Calming chronic sympathetic nervous response
Hyperbaric Oxygen Reduces Aspergillus fumigatus Proliferation In Vitro and
Influences In Vivo Disease Outcomes
Souabh Dhingra, Jay C Buckey, Robert A Cramer Published: March 2018
ABSTRACT: Recent estimates suggest that more than 3 million people have chronic or invasive fungal infections, causing more than 600,000deaths every year.
Aspergillus fumigatus causes invasive pulmonary aspergillosis (IPA) in patients with compromised immune systems and is a primary contributor to increases in human fungal infections. Thus,the development of new clinical modalities as stand-alone or adjunctive therapy for improving IPA patient outcomes is critically needed.
Here we tested the in vitro and in vivo impacts of hyperbaric oxygen (HBO)(100% oxygen,>1atmosphere absolute [ATA]) on A.fumiga-tus proliferation and murine IPA outcomes.
Our findings indicate that HBO reduces established fungal biofilm proliferation in vitro by over 50%.
The effect of HBO under the treatment conditions was transient and fungistatic,with A. fumiga-tus metabolic actvity rebounding within 6 h of HBO treatment being removed.
In vivo,daily HBO provides a dose-dependent but modest improvement in murine IPA disease outcomes as measured by survival analysis.Intriguingly,no synergy was observed between subtherapeutic voriconazole or amphotericin B and HBO in vitro or in vivo with daily HBO dos-ing,though the loss of fungal superoxide dis-mutase genes enhanced HBO antifungal activity.Further studies are needed to optimize the HBO treatment regimen and better understand the effects of HBO on both the host and the pathogen during a pulmonary invasive fungal infection.
